A Study of Gaboxadol in Primary Insomnia
To evaluate the safety and tolerability of gaboxadol in primary insomnia...
Brief Summary
Official Title: “A Prospective Randomised Double-Blind Parallel-Group Placebo-Controlled Study of Gaboxadol in Primary Insomnia”
To evaluate the safety and tolerability of gaboxadol in primary insomnia.
- Study Type: Interventional
- Study Design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Detailed Clinical Trial Description
To obtain long-term safety and tolerability data with gaboxadol.
Intervention(s) in this Clinical Trial
- Drug: Gaboxadol
Outcome Measures for this Clinical Trial
Primary Measures
- Long-term safety in gaboxadol.
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- patients with Primary insomnia
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: 65 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Investigator Information
Lead Investigator: H. Lundbeck A/S Industry
Overall Clinical Trial Officials and Contacts
Please contact: Annelies van der Hammen Legters Study Director H. Lundbeck A/S
Additional Information
Information obtained from ClinicalTrials.gov on February 12, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00209963
Study ID Number: 99784
ClinicalTrials.gov Identifier: NCT00209963
Health Authority: Germany: Federal Institute for Drugs and Medical Devices
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00209963
